• Gaucher Patients, Families Ask to Comment on New Zealand Plan to Switch to Elelyso as Funded ERT
  • Rare Case of Gaucher Disease and Chronic Myeloid Leukemia Reported in Spain
  • FDA Approves Miglustat, 1st Generic Equivalent of Zavesca, to Treat Gaucher Patients
  • ‘Rare Impact Awards’ Dinner Marks Orphan Drug Act and NORD at 35
  • #ECRD2018 – EU Must Do More for Rare Disease Patients, Eurordis Leaders Say
  • Gaucher Type 1 Children Have White Matter Changes in Brain Before Symptoms Appear, Study Shows
  • Lyso-Gb1 Also Reliable Response-to-Therapy Biomarker for Gaucher Patients, Study Finds
  • Fat Accumulation in Brain May Explain Gaucher’s-Parkinson’s Link, Mouse Study Suggests
  • Small Molecule Increases Glucocerebrosidase Activity, May Be Gaucher Therapy
  • #ECRD2018 – Patient Access and Collaboration Focus of Eurordis Meeting May 10-12
  • 3 New Mutations Likely to Cause Gaucher Type 2 Identified in Turkish Study